JP5745274B2 - 抗ヒトｉｌ−２１モノクローナル抗体 - Google Patents

抗ヒトｉｌ−２１モノクローナル抗体 Download PDF

Info

Publication number
JP5745274B2
JP5745274B2 JP2010537542A JP2010537542A JP5745274B2 JP 5745274 B2 JP5745274 B2 JP 5745274B2 JP 2010537542 A JP2010537542 A JP 2010537542A JP 2010537542 A JP2010537542 A JP 2010537542A JP 5745274 B2 JP5745274 B2 JP 5745274B2
Authority
JP
Japan
Prior art keywords
antibody
human
cells
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010537542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506422A5 (cg-RX-API-DMAC7.html
JP2011506422A (ja
Inventor
ステファン アール． ジャスパース
ステファン アール． ジャスパース
マーク ダブリュ． リクソン
マーク ダブリュ． リクソン
ステーシー アール． ディロン
ステーシー アール． ディロン
フレデリック ジェイ． ラムズデル
フレデリック ジェイ． ラムズデル
セシル エム． クレイサ
セシル エム． クレイサ
ユージーン シー． イ
ユージーン シー． イ
Original Assignee
ザイモジェネティクス， インコーポレイテッド
ザイモジェネティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイモジェネティクス， インコーポレイテッド, ザイモジェネティクス， インコーポレイテッド filed Critical ザイモジェネティクス， インコーポレイテッド
Publication of JP2011506422A publication Critical patent/JP2011506422A/ja
Publication of JP2011506422A5 publication Critical patent/JP2011506422A5/ja
Application granted granted Critical
Publication of JP5745274B2 publication Critical patent/JP5745274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
JP2010537542A 2007-12-07 2008-12-08 抗ヒトｉｌ−２１モノクローナル抗体 Active JP5745274B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1232907P 2007-12-07 2007-12-07
US61/012,329 2007-12-07
PCT/IB2008/005011 WO2010055366A2 (en) 2007-12-07 2008-12-08 Anti-human il-21 monoclonal antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014036592A Division JP5848384B2 (ja) 2007-12-07 2014-02-27 抗ヒトｉｌ−２１モノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2011506422A JP2011506422A (ja) 2011-03-03
JP2011506422A5 JP2011506422A5 (cg-RX-API-DMAC7.html) 2011-12-01
JP5745274B2 true JP5745274B2 (ja) 2015-07-08

Family

ID=40899470

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010537542A Active JP5745274B2 (ja) 2007-12-07 2008-12-08 抗ヒトｉｌ−２１モノクローナル抗体
JP2014036592A Active JP5848384B2 (ja) 2007-12-07 2014-02-27 抗ヒトｉｌ−２１モノクローナル抗体
JP2015230496A Active JP6027668B2 (ja) 2007-12-07 2015-11-26 抗ヒトｉｌ−２１モノクローナル抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014036592A Active JP5848384B2 (ja) 2007-12-07 2014-02-27 抗ヒトｉｌ−２１モノクローナル抗体
JP2015230496A Active JP6027668B2 (ja) 2007-12-07 2015-11-26 抗ヒトｉｌ−２１モノクローナル抗体

Country Status (18)

Country Link
US (5) US7883700B2 (cg-RX-API-DMAC7.html)
EP (3) EP2217268B1 (cg-RX-API-DMAC7.html)
JP (3) JP5745274B2 (cg-RX-API-DMAC7.html)
KR (2) KR101591316B1 (cg-RX-API-DMAC7.html)
CN (2) CN102027011B (cg-RX-API-DMAC7.html)
AU (1) AU2008364115B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0821168B8 (cg-RX-API-DMAC7.html)
CA (2) CA2910933C (cg-RX-API-DMAC7.html)
DK (1) DK2217268T3 (cg-RX-API-DMAC7.html)
ES (2) ES2584237T3 (cg-RX-API-DMAC7.html)
HU (1) HUE027828T2 (cg-RX-API-DMAC7.html)
IL (2) IL205976A (cg-RX-API-DMAC7.html)
MX (1) MX2010006181A (cg-RX-API-DMAC7.html)
PL (1) PL2217268T3 (cg-RX-API-DMAC7.html)
PT (1) PT2217268T (cg-RX-API-DMAC7.html)
RU (1) RU2504552C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010055366A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201004046B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2491118T3 (es) 2005-11-28 2014-09-05 Zymogenetics, Inc. Antagonistas de IL-21
PT2217268T (pt) 2007-12-07 2016-07-28 Zymogenetics Inc Anticorpos monoclonais anti-il-21 humana
WO2012012531A2 (en) * 2010-07-20 2012-01-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
US20130323259A1 (en) * 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
US20140170153A1 (en) * 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands
HUE037087T2 (hu) * 2011-10-19 2018-08-28 Morphosys Ag IL17C antagonistái gyulladásos rendellenességek kezelésére
US20140178395A1 (en) * 2012-12-21 2014-06-26 Novo Nordisk A/S Treatment of nephropathy
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
CN105579470B (zh) 2013-06-27 2021-05-25 莫纳什大学 Il-21结合蛋白和其用途
CN103487572B (zh) * 2013-10-08 2017-03-29 北京大学人民医院 滤泡辅助性T淋巴细胞(Tfh)在自身免疫性疾病病情预警中的应用
CN104721820A (zh) * 2013-12-24 2015-06-24 信达生物制药(苏州)有限公司 双特异性单克隆抗体在治疗葡萄膜炎中的用途
WO2015132241A1 (en) * 2014-03-03 2015-09-11 Novo Nordisk A/S Treatment of inflammatory diseases
AR099625A1 (es) 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
RS60795B1 (sr) * 2014-04-08 2020-10-30 Boston Pharmaceuticals Inc Vezujući molekuli specifični za il-21 i njihove upotrebe
PL3139948T3 (pl) * 2014-05-07 2020-08-10 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
HUE048860T2 (hu) * 2014-05-07 2020-09-28 Novo Nordisk As 1-es típusú cukorbetegség kezelése GLP-1 és anti-IL-21 alkalmazásával
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
CN107249633A (zh) * 2014-12-19 2017-10-13 迈博太科公司 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
JP7010833B2 (ja) * 2016-03-31 2022-02-10 イーライ リリー アンド カンパニー Ｉｌ－２１抗体及びその使用
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
JP6952295B2 (ja) * 2016-09-09 2021-10-20 国立大学法人金沢大学 ヒト抗ｈｌａモノクローナル抗体の作製方法
PE20200867A1 (es) 2017-08-03 2020-08-31 Amgen Inc Conjugados que comprende una muteina de interleucina 21 y un anticuerpo anti-pd-1
CA3087273A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4178605A1 (en) * 2020-07-13 2023-05-17 Transgene Treatment of immune depression
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用
WO2025257327A1 (en) 2024-06-13 2025-12-18 Almirall, S.A. Therapeutic approaches for the management of hidradenitis suppurativa

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE60036930T2 (de) 1999-03-09 2008-10-09 Zymogenetics, Inc., Seattle Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
CA2420992C (en) 2000-04-05 2010-07-13 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
DK1717316T3 (da) 2000-06-30 2008-12-08 Zymogenetics Inc Allelisk variant af interferon-lignende protein Zcyto21
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
MEP21708A (en) 2001-05-24 2010-06-10 Zymogenetics Inc Taci-immunoglobulin fusion proteins
WO2003040313A2 (en) * 2001-11-05 2003-05-15 Zymogenetics, Inc Il-21 antagonists
US20040028665A1 (en) * 2002-01-08 2004-02-12 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
EP1531850B1 (en) 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
JP4776228B2 (ja) * 2002-07-15 2011-09-21 ワイス・エルエルシー Ｔヘルパー（ｔｈ）細胞の発生および機能を調節するための方法および組成物
CA2501616C (en) 2002-10-08 2015-05-12 Immunomedics, Inc. Antibody therapy
US20070092485A1 (en) 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
KR101098897B1 (ko) 2002-12-13 2011-12-26 지모제넥틱스, 인코포레이티드 원핵생물 숙주 내 ｉｌ-21 생산
US20080063717A1 (en) 2002-12-23 2008-03-13 Innate Pharma, S.A.S. Pharmaceutical Compositions Having an Effect on the Proliferation of Nk Cells and a Method Using the Same
US7495085B2 (en) * 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
ZA200507235B (en) * 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
EP1680138B1 (en) 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
JP4471721B2 (ja) 2004-04-20 2010-06-02 独立行政法人産業技術総合研究所 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ
CA2566333A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
KR20070057789A (ko) 2004-08-05 2007-06-07 와이어쓰 인터루킨-21 수용체 활성의 상쇄
KR100654124B1 (ko) 2004-11-18 2006-12-08 주식회사 하이닉스반도체 벙커 디펙트를 억제할 수 있는 반도체 소자 제조 방법
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
DK200501310A (da) * 2005-09-21 2005-10-01 Novo Nordisk As The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults
WO2007114861A2 (en) 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
ES2491118T3 (es) 2005-11-28 2014-09-05 Zymogenetics, Inc. Antagonistas de IL-21
PT2217268T (pt) 2007-12-07 2016-07-28 Zymogenetics Inc Anticorpos monoclonais anti-il-21 humana

Also Published As

Publication number Publication date
US8241629B2 (en) 2012-08-14
US20120225065A1 (en) 2012-09-06
CA2707026A1 (en) 2010-05-20
BRPI0821168B1 (pt) 2021-01-12
KR20100097724A (ko) 2010-09-03
US20100041873A1 (en) 2010-02-18
JP6027668B2 (ja) 2016-11-16
ES2572231T3 (es) 2016-05-30
BRPI0821168B8 (pt) 2021-05-25
RU2010123049A (ru) 2012-01-20
CA2910933C (en) 2017-04-11
WO2010055366A2 (en) 2010-05-20
WO2010055366A3 (en) 2010-10-21
IL239947A (en) 2016-03-31
US8226948B1 (en) 2012-07-24
KR101591316B1 (ko) 2016-02-05
IL205976A0 (en) 2010-11-30
KR101615215B1 (ko) 2016-04-25
HUE027828T2 (en) 2016-11-28
US20120177655A1 (en) 2012-07-12
US8124089B2 (en) 2012-02-28
JP2014129387A (ja) 2014-07-10
KR20160022386A (ko) 2016-02-29
WO2010055366A4 (en) 2012-08-16
US20110130548A1 (en) 2011-06-02
PL2217268T3 (pl) 2016-12-30
PT2217268T (pt) 2016-07-28
US8361470B2 (en) 2013-01-29
DK2217268T3 (en) 2016-08-15
AU2008364115B2 (en) 2013-11-21
CN103772502B (zh) 2017-03-29
JP5848384B2 (ja) 2016-01-27
CA2707026C (en) 2017-04-11
CA2910933A1 (en) 2010-05-20
CN102027011B (zh) 2014-09-03
IL239947A0 (en) 2015-08-31
IL205976A (en) 2015-08-31
JP2011506422A (ja) 2011-03-03
EP2217268B1 (en) 2016-05-04
EP2217268A2 (en) 2010-08-18
AU2008364115A1 (en) 2010-05-20
ES2584237T3 (es) 2016-09-26
US7883700B2 (en) 2011-02-08
EP2426146A3 (en) 2012-05-30
MX2010006181A (es) 2010-07-01
JP2016033150A (ja) 2016-03-10
EP2426146A2 (en) 2012-03-07
US20090191214A1 (en) 2009-07-30
BRPI0821168A2 (pt) 2015-10-27
EP2426146B1 (en) 2016-02-17
EP3103813A1 (en) 2016-12-14
CN103772502A (zh) 2014-05-07
CN102027011A (zh) 2011-04-20
ZA201004046B (en) 2011-04-28
RU2504552C2 (ru) 2014-01-20

Similar Documents

Publication Publication Date Title
JP6027668B2 (ja) 抗ヒトｉｌ−２１モノクローナル抗体
JP6163520B2 (ja) Ｉｌ−２１アンタゴニスト
JP2009517406A (ja) Ｉｌ−２１受容体アンタゴニスト
HK1167661A (en) Anti-human il-21 monoclonal antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150501

R150 Certificate of patent or registration of utility model

Ref document number: 5745274

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250